Compliance to recommended liver function monitoring in patients on statin therapy

Cardiovascular Therapeutics

Volumn 27, Issue 2, 2009, Pages 96-100

  Leaver, Heather ^a   Keng Lim, Tiong ^a   Thomson, Philip ^a   Leaver, Joanne ^a   Choy, Anna M J ^a   Lang, Chim C ^a,b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adverse drug reactions; Drug safety monitoring; Hepatoxicity; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; LABORATORY TEST; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL PRACTICE; PATIENT MONITORING; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; UNITED KINGDOM;

AGED; ALANINE TRANSAMINASE; CLINICAL ENZYME TESTS; DRUG LABELING; DRUG MONITORING; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SCOTLAND;

EID: 65549123241     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00082.x     Document Type: Article

References (22)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998 279 : 1200 1205.
2. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004 329 : 15 19.
3. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995 155 : 1949 1956.
4. Pirmohamed M, Ferner RE. Monitoring drug treatment. BMJ 2003 327 : 1179 1181.
5. The British National Formulary 2008. Available at : http://www.bnf.org (accessed November 2008).
6. Scottish intercollegiate guidelines guideline 40 lipids and the primary prevention of coronary heart disease. Available at : http://www.sign.ac.uk (accessed September 1999).
7. Scottish intercollegiate guidelines network 97. Risk estimation and the prevention of cardiovascular disease. Available at : http://www.sign.ac.uk/ guidelines/fulltext/97/index.html (accessed February 2007).
8. Pasternak RC, Smith SC Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002 106 : 1024 1028.
9. Walley T, Folino-Gallo P, Schwabe U, van Ganse E. Variations and increase in use of statins across europe: Data from administrative databases. BMJ 2004 328 : 385 386.
10. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004 292 : 2585 2590.
11. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003 289 : 1681 1690.
12. Gotto AM Jr. Safety and statin therapy: Reconsidering the risks and benefits. Arch Intern Med 2003 163 : 657 659.
13. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: The yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003 163 : 688 692.
14. Pedersen TR, Tobert JA. Benefits and risks of hmg-coa reductase inhibitors in the prevention of coronary heart disease: A reappraisal. Drug Saf 1996 14 : 11 24.
15. Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc (2003) 2006 46 : 479 488 quiz 488-490.
16. Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 2001 322 : 276 278.
17. Dujovne CA. Side effects of statins: Hepatitis versus "Transaminitis"-myositis versus "Cpkitis". Am J Cardiol 2002 89 : 1411 1413.
18. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective pravastatin pooling (PPP) project. Circulation 2002 105 : 2341 2346.
19. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals. A randomised placebo-controlled trial. Lancet 2002 360 : 23 33.
20. Cullen DJ, Bates DW, Small SD, Cooper JB, Nemeskal AR, Leape LL. The incident reporting system does not detect adverse drug events: A problem for quality improvement. Jt Comm J Qual Improv 1995 21 : 541 548.
21. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: Development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998 5 : 305 314.
22. Honigman B, Light P, Pulling RM, Bates DW. A computerized method for identifying incidents associated with adverse drug events in outpatients. Int J Med Inform 2001 61 : 21 32.